1. Home
  2. DMAC vs PROC Comparison

DMAC vs PROC Comparison

Compare DMAC & PROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • PROC
  • Stock Information
  • Founded
  • DMAC 2000
  • PROC 1976
  • Country
  • DMAC United States
  • PROC Luxembourg
  • Employees
  • DMAC N/A
  • PROC N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • PROC Biotechnology: Pharmaceutical Preparations
  • Sector
  • DMAC Health Care
  • PROC Health Care
  • Exchange
  • DMAC Nasdaq
  • PROC Nasdaq
  • Market Cap
  • DMAC 224.6M
  • PROC 253.9M
  • IPO Year
  • DMAC N/A
  • PROC N/A
  • Fundamental
  • Price
  • DMAC $5.80
  • PROC $1.65
  • Analyst Decision
  • DMAC Strong Buy
  • PROC
  • Analyst Count
  • DMAC 3
  • PROC 0
  • Target Price
  • DMAC $7.00
  • PROC N/A
  • AVG Volume (30 Days)
  • DMAC 100.7K
  • PROC 31.5K
  • Earning Date
  • DMAC 03-18-2025
  • PROC 01-01-0001
  • Dividend Yield
  • DMAC N/A
  • PROC N/A
  • EPS Growth
  • DMAC N/A
  • PROC N/A
  • EPS
  • DMAC N/A
  • PROC 0.52
  • Revenue
  • DMAC N/A
  • PROC $414,096,000.00
  • Revenue This Year
  • DMAC N/A
  • PROC $5.54
  • Revenue Next Year
  • DMAC N/A
  • PROC $8.54
  • P/E Ratio
  • DMAC N/A
  • PROC $3.32
  • Revenue Growth
  • DMAC N/A
  • PROC N/A
  • 52 Week Low
  • DMAC $2.14
  • PROC $0.50
  • 52 Week High
  • DMAC $6.41
  • PROC $4.38
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 58.22
  • PROC 41.20
  • Support Level
  • DMAC $5.25
  • PROC $2.21
  • Resistance Level
  • DMAC $5.85
  • PROC $1.80
  • Average True Range (ATR)
  • DMAC 0.39
  • PROC 0.17
  • MACD
  • DMAC 0.01
  • PROC -0.08
  • Stochastic Oscillator
  • DMAC 73.02
  • PROC 17.05

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

About PROC Procaps Group S.A.

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Share on Social Networks: